Lipid nanoparticles are the small fatty bubbles that carried the COVID-19 vaccines into roughly five billion arms, and they are now the delivery vehicle of choice for a growing pipeline of mRNA therapies, gene editors, and cancer treatments. They are also a manufacturing headache. Purifying them at scale tends to involve tangential flow filtration and ultracentrifugation, processes that are slow, lossy, and expensive enough that the purification step alone can dominate the cost of goods for a clinical batch.
Amplify Dynamics, a pre-seed company founded by University of Chicago molecular engineer Gustavo, thinks there is a better way to do it with sound. The company is developing ultrafiltration hardware that uses acoustofluidics, the manipulation of particles inside microfluidic channels using ultrasonic standing waves, to separate lipid nanoparticles from process impurities [Amplify Dynamics]. The pitch to drug developers is straightforward: cleaner particles, less product loss, and a continuous process instead of a batch one.
The bet
Amplify is selling picks and shovels to the mRNA industry. The core technology was invented during Gustavo's doctoral work at the University of Chicago and is now being commercialized as purification equipment for biotech and pharma manufacturers working on lipid nanoparticle (LNP) formulations [Amplify Dynamics]. According to The Ganesha Lab, the Latin American biotech accelerator that backed the company, the goal is "delivering ultra-pure lipid nanoparticles to accelerate the development of life-saving therapies" [The Ganesha Lab].
Why it could be big
The market tailwind is the one biotech investors have been writing memos about since 2021. Moderna, BioNTech, Pfizer, and a long tail of clinical-stage startups are all building LNP-based programs that go well beyond infectious disease vaccines, into oncology, rare disease, and gene editing. Every one of those programs needs purified material at IND-enabling scale, and most of them either run their purification in-house on legacy equipment or outsource it to contract manufacturers using the same techniques.
Backing Amplify at this stage is The Ganesha Lab, which announced its investment to support the company's purification work [The Ganesha Lab]. The funding is structured as non-equity assistance with rounds recorded in January 2024 and February 2025 [Crunchbase].
Back of envelope
A single clinical batch of an mRNA-LNP drug product can run into the millions of dollars in raw materials and processing, and industry presentations have put downstream purification at roughly 20 to 40 percent of LNP manufacturing cost. On a $2M batch, that is $400k to $800k in purification alone. If an acoustofluidic system improves yield by even 10 percentage points, the recovered product on a single batch is worth more than most pieces of capital equipment in the suite.
The team
Gustavo is co-founder and CEO, and is described as a molecular engineer and the inventor of the core technology [Amplify Dynamics]. Sebastian Saldarriaga M is also associated with the company [LinkedIn].
| Round | Date | Amount | Source |
|---|---|---|---|
| Non-equity assistance | Jan 2024 | Undisclosed | Crunchbase |
| Non-equity assistance | Feb 2025 | Undisclosed | Crunchbase |
The honest counterfactual
What skeptics will say: acoustofluidic separation has been an active academic field for two decades, and translating it into bioprocessing equipment that scales from microliters to the liters-per-hour throughput a commercial LNP suite needs is the part everyone underestimates. The bull answer, supported by the company's positioning and The Ganesha Lab's thesis, is that Amplify is not asking customers to retool a whole facility. It is offering a purification module that slots into the downstream train and earns its keep on yield and product quality [The Ganesha Lab].
What to watch
The near-term milestones are technical and commercial. First, a peer-reviewed or customer-validated demonstration of throughput and recovery on a real LNP formulation. Second, a paid pilot with a CDMO or a clinical-stage mRNA developer. Third, a hire on the bioprocess side who has sold capital equipment into pharma before. If Amplify clears those three in the next twelve to eighteen months, the non-equity assistance from The Ganesha Lab will look like a well-placed early bet on a category that the industry quietly needs.